Many states have approved medical marijuana for the treatment of Tourette's syndrome, including Arkansas, Illinois, Minnesota, Missouri, New Jersey, and Ohio. While some individuals have reported reduced ticks when using medical marijuana, others have reported no effect at all or even adverse reactions. At present, the Tourette Association of America has formed a cannabis consortium to better understand the role of medical marijuana for this purpose. Fundamentally, multiple medications have been approved by the FDA for the treatment of Tourette's syndrome, but these medications have been shown to have significant side effects, including a belief that symptoms are not adequately controlled. At present, research is continuing on this topic, and most of the current research has come out of Canada. This site will seek to identify and delineate research across Canada, the United States, and internationally, as available.
Szejko, N., Saramak, K., Lombroso, A., & Müller-Vahl, K. R. (2022). Cannabis-based medicine in treatment of patients with Gilles de la Tourette syndrome. Polish Journal of Neurology and Neurosurgery, 56(1), 28-38. https://doi.org/10.5603/PJNNS.a2021.0081
Abi-Jaoude, E., Chen, L., Cheung, P., Bhikram, T., & Sandor, P. (2017). Preliminary evidence on cannabis effectiveness and tolerability for adults with Tourette syndrome. The Journal of Neuropsychiatry and Clinical Neurosciences, 29(4), 391-400. https://doi.org/10.1176/appi.neuropsych.16110310
Müller-Vahl, K. R. (2013). Treatment of Tourette syndrome with cannabinoids. Behavioural Neurology, 27(1), 119-124. https://doi.org/10.3233/BEN-120276
Copyright © 2023 Marijuana Scholar - All Rights Reserved.